Jefferies Financial Group Boosts Intuitive Surgical (NASDAQ:ISRG) Price Target to $375.00

Intuitive Surgical (NASDAQ:ISRG) had its price objective increased by Jefferies Financial Group from $365.00 to $375.00 in a report released on Friday, Benzinga reports. They currently have a hold rating on the medical equipment provider’s stock.

Several other research firms have also recently commented on ISRG. Royal Bank of Canada upped their target price on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an outperform rating in a research note on Wednesday, January 24th. Truist Financial upped their target price on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a buy rating in a research note on Wednesday, January 24th. Citigroup upped their target price on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a buy rating in a research note on Wednesday, April 3rd. Raymond James upped their target price on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an outperform rating in a research note on Thursday, January 25th. Finally, StockNews.com cut shares of Intuitive Surgical from a buy rating to a hold rating in a research note on Thursday, February 29th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, Intuitive Surgical currently has an average rating of Moderate Buy and an average price target of $396.17.

Intuitive Surgical Trading Down 1.7 %

Shares of Intuitive Surgical stock opened at $366.34 on Friday. The firm has a fifty day simple moving average of $386.84 and a 200-day simple moving average of $343.10. Intuitive Surgical has a 1-year low of $254.85 and a 1-year high of $403.76. The stock has a market capitalization of $129.85 billion, a price-to-earnings ratio of 66.13, a PEG ratio of 5.78 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 13.27%. Intuitive Surgical’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.00 earnings per share. As a group, research analysts predict that Intuitive Surgical will post 4.93 earnings per share for the current year.

Insider Activity

In other news, EVP Myriam Curet sold 4,318 shares of the firm’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $370.15, for a total value of $1,598,307.70. Following the transaction, the executive vice president now owns 189 shares of the company’s stock, valued at approximately $69,958.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Myriam Curet sold 4,318 shares of the firm’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $370.15, for a total value of $1,598,307.70. Following the transaction, the executive vice president now owns 189 shares of the company’s stock, valued at approximately $69,958.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $370.20, for a total transaction of $740,400.00. Following the completion of the transaction, the director now directly owns 25,319 shares in the company, valued at approximately $9,373,093.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 248,418 shares of company stock valued at $95,927,097. 0.90% of the stock is currently owned by insiders.

Institutional Trading of Intuitive Surgical

Several hedge funds have recently bought and sold shares of the stock. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its holdings in Intuitive Surgical by 0.3% during the 4th quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock worth $3,002,000 after buying an additional 27 shares during the period. Advance Capital Management Inc. raised its holdings in Intuitive Surgical by 3.8% during the 1st quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock worth $295,000 after buying an additional 27 shares during the period. Sheaff Brock Investment Advisors LLC grew its stake in shares of Intuitive Surgical by 1.3% during the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 2,226 shares of the medical equipment provider’s stock worth $751,000 after acquiring an additional 29 shares in the last quarter. Liberty Capital Management Inc. grew its stake in shares of Intuitive Surgical by 3.8% during the 4th quarter. Liberty Capital Management Inc. now owns 815 shares of the medical equipment provider’s stock worth $275,000 after acquiring an additional 30 shares in the last quarter. Finally, NBC Securities Inc. grew its stake in shares of Intuitive Surgical by 34.4% during the 1st quarter. NBC Securities Inc. now owns 121 shares of the medical equipment provider’s stock worth $48,000 after acquiring an additional 31 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.